GLP-1 diabetes drugs linked to reduced risk of addiction and substance-related death
Findings suggest a potential role in both prevention and treatment of various substance use disorders, say researchers Glucagon-like peptide-1 (GLP-1) receptor agonists used to treat type 2 diabetes and obesity may also help to lower the risk of addiction to a range of substances including alcohol, cannabis, cocaine, nicotine, and ...

